Search Results 1151-1160 of 17725 for Blind spot
This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
Rodolfo Savica, M.D., Ph.D., studies biomarkers and risk factors to improve diagnosis and treatment of early-onset Parkinson's and related disorders.
The findings from these observations will contribute to the development of measures to evaluate shared decision making (SDM) and unhurried conversations.
Large-scale exome sequencing project spots disease-fueling mutations to save lives, accelerate discoveries. Susan Murphy. October 18, 2021. Science Saturday ...
The purpose of this study is to understand the aqueous humor dynamics changes that occur with glaucoma therapies and provocative tests. Participation ...
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy.
About this study. The purpose of this study is to quantify potential decreases in visual acuity experienced by patients who experience mid-day fogging ...
Mayo Clinic Minute: What is an aneurysm? Mayo Clinic Research Finds Risk of Glaucoma Blindness Drops by Half · New Way to Fix Aneurysms · Optic neuritis ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!